Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2235 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PF-03622905
CAS:<p>PF-03622905: potent ATP-competitive PKC inhibitor, IC50: 5.6-74.1 nM for PKCα/βI/βII/γ/θ, high specificity for PKC.</p>Formula:C24H35N7O3Color and Shape:SolidMolecular weight:469.59Ep300/CREBBP-IN-8
CAS:<p>Ep300/CREBBP-IN-8, IC50: 0.014/0.018 μM, potent Ep300/CREBBP inhibitor, oral, for cancer research.</p>Formula:C25H27F2N5O3Color and Shape:SolidMolecular weight:483.51BRCA1-IN-1
CAS:<p>BRCA1-IN-1 is a novel small-molecule-like inhibitor of BRCA1 (IC50: 0.53 μM; Ki: 0.71 μM).</p>Formula:C27H33F2N4O6PPurity:98%Color and Shape:SolidMolecular weight:578.54HDAC-IN-68 hydrochloride
<p>HDAC-IN-68 (hydrochloride) (Compound 29) is an HDACs inhibitor with an IC50 value of 0.04 μM and induces microtubule fragmentation by activating katanin, a microtubule-severing protein. It is applicable in cancer research.</p>Formula:C27H25ClN8O6Molecular weight:592.15856Biguanide
CAS:<p>Biguanide can reduce oxidative stress in rats with hyperglycemia.</p>Formula:C2H7N5Color and Shape:SolidMolecular weight:101.11BRD3067
CAS:<p>BRD3067, a Tubacin derivative, inhibits HDAC6 (IC50 15 nM) and acts as a negative control for Tubacin A, showing anticancer and anti-inflammatory effects.</p>Formula:C21H23N3O2Purity:98%Color and Shape:SolidMolecular weight:349.43Bryostatin 3
CAS:<p>Bryostatin 3 is a protein kinase C activator.</p>Formula:C46H64O17Purity:98%Color and Shape:SolidMolecular weight:888.99MSC2504877
CAS:<p>MSC2504877 inhibits tankyrase, boosts CDK4/6 inhibitors, blocks Cyclin D2/E2 upregulation, and strengthens phospho-Rb suppression.</p>Formula:C17H18N2O2Purity:99.72%Color and Shape:SoildMolecular weight:282.34pan-BET/BD2-IN-1
<p>Pan-BET/BD2-IN-1 (compound 6b) is a selective BET protein inhibitor with BRDT-1Ki of 1.05 μM and BRD4-1Ki of 0.68 μM. It effectively inhibits the growth of MM.1S cancer cells with an IC50 value of 2.6 μM.</p>Color and Shape:Odour SolidPOI ligand 1
<p>POI ligand 1 serves as a template for the non-selective HDAC inhibitor Vorinostat. It functions as a target protein ligand (PROTAC target protein ligand) in the creation of PROTAC HDAC degraders with anti-tumor properties. Additionally, POI ligand 1 is utilized in the synthesis of FF2049.</p>Formula:C14H21N3O3Color and Shape:SolidMolecular weight:279.335SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94BRD4 degrader AT1
CAS:<p>BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.</p>Formula:C48H58ClN9O5S3Purity:98%Color and Shape:SolidMolecular weight:972.68Malantide
CAS:<p>Malantide, a synthetic dodecapeptide, boosts and measures PKA activity by undergoing PKA-induced phosphorylation.</p>Formula:C72H124N22O21Purity:98%Color and Shape:SolidMolecular weight:1633.89dBET23
CAS:<p>dBET23 is a BRD4 degrader.</p>Formula:C43H45ClN8O9SColor and Shape:SolidMolecular weight:885.38CD532 hydrochloride
<p>CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.</p>Color and Shape:SolidmTOR/HDAC-IN-1
CAS:<p>mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.</p>Formula:C23H23N11O3Color and Shape:SolidMolecular weight:501.5MT1
CAS:<p>MT1, a bivalent chemical probe targeting BET bromodomains, demonstrates an IC50 value of 0.789 nM for BRD4(1).</p>Formula:C54H66Cl2N10O9S2Color and Shape:SolidMolecular weight:1134.2XF056-132
CAS:<p>XF056-132 is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader [1] .</p>Formula:C51H57F4N9O7SColor and Shape:SolidMolecular weight:1016.11HDAC-IN-26
CAS:<p>HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC 50 value of 4.7 nM.</p>Formula:C24H28FN5O3Color and Shape:SolidMolecular weight:453.518CBP/p300-IN-14
CAS:<p>CBP/p300-IN-14, patent WO2021213521A1's compound 27, inhibits CBP/EP300 with 3.3 nM IC50.</p>Formula:C30H31F2N7O2Color and Shape:SolidMolecular weight:559.622MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formula:C25H38N4O3Color and Shape:SolidMolecular weight:442.59Ep300/CREBBP-IN-2
CAS:<p>Ep300/CREBBP-IN-2: Potent, oral Ep300 & CREBBP inhibitor; IC50s: 0.052μM & 0.148μM; cancer research.</p>Formula:C26H27F3N4O4Color and Shape:SolidMolecular weight:516.51mUNO
CAS:<p>mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.</p>Formula:C22H39N7O8SColor and Shape:SolidMolecular weight:561.652EZH2-IN-15
CAS:<p>A compound inhibits EZH2, overexpressed in cancers, affecting Treg activity and innate immunity.</p>Formula:C32H44N4O4Purity:99.88%Color and Shape:SolidMolecular weight:548.72ATF3 inducer 1
CAS:<p>ATF3 inducer 1 is an ATF3 inducer with lipid-lowering activity, alleviating glucose intolerance and insulin resistance induced by high-fat diet (HFD).</p>Formula:C12H10N2O3Purity:99.04%Color and Shape:SoildMolecular weight:230.22HD-TAC7
<p>HD-TAC7 is a PROTAC HDAC degrader; IC50s: HDAC1 (3.6μM), HDAC2 (4.2μM), HDAC3 (1.1μM); reduces NF-κB p65; researched for asthma, COPD.</p>Formula:C33H32FN7O7Color and Shape:SolidMolecular weight:657.65OARV-771
CAS:<p>OARV-771: VHL-based PROTAC targeting BET; DC50: Brd4-6nM, Brd2-1nM, Brd3-4nM; enhanced cell permeability.</p>Formula:C49H59ClN8O8S2Color and Shape:SolidMolecular weight:987.62(S,R,S)-AHPC-C5-COOH
CAS:<p>E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.</p>Formula:C29H42N4O5SPurity:98%Color and Shape:SolidMolecular weight:558.73PROTAC SMARCA2/4-degrader-27
CAS:<p>PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.</p>Formula:C49H58FN9O6SColor and Shape:SolidMolecular weight:920.11Cath-L-dBET1
<p>Cath-L-dBET1 is a PROTAC degrader targeting BRD4. It has an IC50 value of 2.8 μM in MDA-MB-231 cells. Activated by cathepsin L (Cath-L), Cath-L-dBET1 recruits E3 ubiquitin ligase to degrade BRD4 via the ubiquitin-proteasome system. Hyp-dBET1 is applicable for antitumor research.</p>Color and Shape:Odour SolidJHDM-IN-1
CAS:<p>JHDM-IN-1 inhibits JHDMs; IC50: 3.4 μM JMJD2C, 4.3 μM JMJD2A, 5.9 μM JMJD2E, 10 μM PHF8, 43 μM JMJD3.</p>Formula:C27H29N3O6Color and Shape:SolidMolecular weight:491.54ZINC000014708529
<p>ZINC000014708529 is a potent SIRT7 inhibitor exhibiting high affinity for SIRT7 and is utilized in cancer research [1].</p>Color and Shape:Odour SolidSIRT1/2/3-IN-1
CAS:<p>Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.</p>Formula:C46H63N9O8S2Color and Shape:SolidMolecular weight:934.18NF-κB/HIF-1α-IN-1
<p>NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.</p>Formula:C24H27N7O4Color and Shape:SolidMolecular weight:477.21245MZP-55
CAS:<p>MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)</p>Formula:C57H70ClN7O10SPurity:98%Color and Shape:SolidMolecular weight:1080.73TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485N-Desmethyltamoxifen
CAS:<p>N-Desmethyltamoxifen, tamoxifen's main human metabolite, regulates AML cell ceramide metabolism and is a more potent PKC inhibitor than tamoxifen.</p>Formula:C25H27NOPurity:98%Color and Shape:SolidMolecular weight:357.49AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Formula:C28H32FN9O2Color and Shape:SolidMolecular weight:545.61MS2133
<p>MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.</p>Formula:C58H66ClF3N14O11S2Color and Shape:SolidMolecular weight:1290.41175OKI-006
CAS:<p>OKI-006 is an oral HDAC inhibitor with potential for cancer research, derived from largazole.</p>Formula:C21H30N4O5S2Color and Shape:SolidMolecular weight:482.62PROTAC SMARCA2/4-degrader-31
CAS:<p>PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.</p>Formula:C44H51N11O4Color and Shape:SolidMolecular weight:797.95PROTAC BRD4-binding moiety 1
CAS:<p>BRD4-binding moiety 1 links to cereblon, forming a PROTAC that degrades BRD4 efficiently.</p>Formula:C23H21N3O2Purity:98%Color and Shape:SolidMolecular weight:371.43(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
CAS:<p>(S,R,S)-AHPC-C2-amide targets Smad3 degradation and boosts HIF-α; it has anti-fibrotic and renal protective roles.</p>Formula:C41H46N6O6SColor and Shape:SolidMolecular weight:750.91SGC3027
<p>SGC3027 is an inhibitor of histone methyltransferase,also is a first potent, selective and cell active chemical probe for PRMT7.</p>Formula:C41H47ClN6O6SPurity:98%Color and Shape:SolidMolecular weight:787.37(rel)-Tranylcypromine D5 hydrochloride
CAS:<p>(rel)-Tranylcypromine D5 hydrochloride is a deuterium labeled (rel)-Tranylcypromine hydrochloride.</p>Formula:C9H12ClNPurity:98%Color and Shape:SolidMolecular weight:174.682TAS-119
CAS:<p>TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95</p>Formula:C23H22Cl2FN5O3Purity:99.65%Color and Shape:SolidMolecular weight:506.36KDM4 ligand-1
<p>KDM4ligand-1 is a ligand targeting the protein (histone lysine demethylase KDM4) in PROTACs. It can be utilized for the synthesis of PROTACs.</p>Color and Shape:Odour SolidEchinomycin
CAS:<p>Echinomycin (Quinomycin A) is a quinoxaline antibiotic and a DNA-intercalating peptide that inhibits hypoxia-inducible factor-1 (HIF-1) DNA binding activity.</p>Formula:C51H64N12O12S2Purity:95%Color and Shape:SolidMolecular weight:1101.26
